Alector(NASDAQ) ALEC

Market Cap$218.85M

Since IPO (2019)-89%

5 Year-93%

1 Year-20%

1 Month+31%

$1.96

-3.92%

-0.08Today

After hours$2.09+$0.13 (+6.63%)

Alector last closing stock price
Metric	Price	Date
Last close	USD 1.96	2026-08-14

Alector stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+10.11%	USD 1.78	2026-08-07
1 month	+30.67%	USD 1.50	2026-07-15
3 month	-9.26%	USD 2.16	2026-05-15
Year to date	+25.64%	USD 1.56	2025-12-31
1 year	-20.33%	USD 2.46	2025-08-14
3 year	-73.8%	USD 7.48	2023-08-15
5 year	-93.08%	USD 28.32	2021-08-13
Since inception	-89.11%	USD 18.00	2019-02-07

Alector Financials at a Glance

Market Cap

$218.85M

Revenue (TTM)

$13.86M

Net Income (TTM)

-$117.85M

EPS (TTM)

-$1.09

P/E Ratio

-1.79

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.96

Volume

649,021

Open

$2.04

Price

$1.96

Volume

649,021

Open

$2.04

Previous Close

$1.96

Daily Range

$1.95 - $2.07

52-Week Range

$1.09 - $3.40

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.96

Volume

649,021

Open

$2.04

Previous Close

$1.96

Daily Range

$1.95 - $2.07

52-Week Range

$1.09 - $3.40

Estimated Earnings Date

Nov 5, 2026

ALEC News

What Company Will Eli Lilly Buy Next?

David HaenJan 23, 2020

Biotech’s Year-End To-Do List

David HaenDec 7, 2019

Page 1

ALEC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alector

Alector makes medicines to fight brain diseases. These treatments help people with Alzheimer's and Parkinson's. The company works to stop brain cells from dying.

Fighting Brain Diseases

Alector Brain Carrier: Proprietary technology designed to transport drugs across the blood-brain barrier, which acts as the brain's protective wall.
Progranulin-Elevating Antibodies: Drugs like latozinemab that increase levels of progranulin, a protein essential for brain cell health.
siRNA Platform: Small interfering RNA technology that stops the body from creating toxic proteins linked to dementia.
Enzyme Replacement Therapy: Program AL050 features an engineered enzyme intended to treat Parkinson's disease and Lewy body dementia.

Growth and Funding Deals

Partnered with GlaxoSmithKline in July 2021 to develop antibodies for neurodegenerative conditions.
Updated the GlaxoSmithKline agreement in May 2023 to share research costs for certain clinical trials.
Secured a $50 million loan facility from Hercules Capital in November 2024 to support operations.
Raised $20 million in net proceeds through a stock sale agreement with TD Securities.

How Alector Stands Out

Alector uses its brain carrier technology to bypass the brain's natural protective wall. This allows therapeutics like antibodies and enzymes to reach brain tissue more effectively.

The Quarterly Scorecard

Revenue was $1 million in Q1 2026, down 71.5% from $3.7 million in Q1 2025.
Net loss narrowed 43.3% to $22.9 million for the period ended March 31, 2026.
Research and development spending decreased by $15.8 million year-over-year following staff cuts in 2025.
Cash and marketable securities totaled $206.5 million at the end of March 2026.
Free cash flow improved 17.9% to negative $49.9 million in the first quarter of 2026.

Bottom Line

Alector has shifted its focus to its proprietary brain-delivery platform following recent late-stage clinical trial failures. The company maintains its operations through strategic partnerships and existing cash reserves.

AI Generated • May 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

103

CEO

Arnon Rosenthal, PhD

Website

www.alector.com

Headquarters

South San Francisco, CA 94080, US

ALEC Financials

Key Financial Metrics (TTM)

Gross Margin

-360.92%

Operating Margin

-914.56%

Net Income Margin

-850.13%

Return on Equity

-531.04%

Return on Capital

-218.01%

Return on Assets

-58.10%

Earnings Yield

-55.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$218.85M

Shares Outstanding

111.66M

Volume

649.02K

Avg. Volume

904.30K

Financials (TTM)

Gross Profit

-$50.03M

Operating Income

-$126.79M

EBITDA

-$107.84M

Operating Cash Flow

-$158.23M

Capital Expenditure

-$160.00K

Free Cash Flow

-$158.39M

Cash & ST Invst.

$172.80M

Total Debt

$32.76M

Alector Performance Analysis

Alector annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 133,617,000	-35.5%
2023	2023-12-31	USD 97,062,000	-27.4%
2024	2024-12-31	USD 100,558,000	3.6%
2025	2025-12-31	USD 21,045,000	-79.1%

Alector sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-58.6%
Q4	2025-12-31	91.3%
Q1	2026-03-31	-83.2%
Q2	2026-06-30	217.4%

Alector annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.62	257.8%
2023	2023-12-31	USD -1.56	-3.7%
2024	2024-12-31	USD -1.23	-20.9%
2025	2025-12-31	USD -1.39	12.6%

Alector sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-13.3%
Q4	2025-12-31	N/A
Q1	2026-03-31	38.2%
Q2	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$3.32M

-57.8%

Gross Profit

$3.32M

+116.8%

Gross Margin

100.00%

N/A

Market Cap

$218.85M

N/A

Market Cap/Employee

$2.12M

N/A

Employees

103

N/A

Net Income

-$22.99M

+24.7%

EBITDA

-$18.73M

+31.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$172.80M

-43.8%

Total Debt

$32.76M

-17.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$13.70M

-55.2%

Short Term Debt

$19.06M

+114.0%

Return on Assets

-58.10%

N/A

Return on Invested Capital

-75.19%

N/A

Free Cash Flow

-$34.25M

+30.2%

Operating Cash Flow

-$34.22M

+30.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PEPGPepGen Inc.

PEPGPepGen Inc.$2.99+0.34%

ABOSAcumen Pharmaceuticals, Inc.

ABOSAcumen Pharmaceuticals, Inc.$2.67+4.71%

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBPCorbus Pharmaceuticals Holdings, Inc.$10.09+0.10%

NKTXNkarta, Inc.

NKTXNkarta, Inc.$2.33+1.30%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$4.21+0.00%

IRDOpus Genetics, Inc.

IRDOpus Genetics, Inc.$3.61-2.96%

FATEFate Therapeutics, Inc.

FATEFate Therapeutics, Inc.$2.57+1.98%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NUNu Holdings

NUNu Holdings$15.23+0.09%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.76+0.01%

ONDSOndas

ONDSOndas$9.24+0.04%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$140.00-0.01%

INTCIntel

INTCIntel$102.50-0.02%

NVDANvidia

NVDANvidia$225.16-0.00%

NOKNokia

NOKNokia$10.76+0.02%

Questions About ALEC

What is the current price of Alector?

Alector is trading at $1.96 per share.

What is the 52-week range for Alector?

Over the past 52 weeks, Alector has traded between $1.09 and $3.40.

How much debt does Alector have?

As of the most recent reporting period, Alector reported total debt of $32.76M.

How much cash does Alector have on hand?

Alector reported $59.92M in cash and cash equivalents in its most recent financial results.

What is Alector’s dividend yield?

Alector does not currently have a dividend yield.

Alector(NASDAQ) ALEC

Alector Financials at a Glance

ALEC News

Alector (ALEC) Q2 Revenue Falls 48%

Why Alector Shares Are Diving Today

Why Alector Zoomed 12% Higher Today

Why Alector Blasted Higher Today

Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring

Why Alector Is Tumbling 28.7% Today

What Company Will Eli Lilly Buy Next?

Biotech’s Year-End To-Do List

ALEC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Alector

Fighting Brain Diseases

Growth and Funding Deals

How Alector Stands Out

The Quarterly Scorecard

Bottom Line

ALEC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Alector Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALEC

What is the current price of Alector?

What is the 52-week range for Alector?

How much debt does Alector have?

How much cash does Alector have on hand?

What is Alector’s dividend yield?

Premium Investing Services